Nanjing King-Friend Biochemical Pharmaceutical (603707.SH): Rocuronium Bromide Injection Obtains Drug Registration Certificate.
Jianniu Corporation (603707.SH) announced that the company recently received the approval for Rocuronium Bromide issued by the National Medical Products Administration.
Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) announced that the company has recently received the drug registration certificate for Rocuronium Bromide Injection 5ml:50mg and 10ml:100mg issued by the National Medical Products Administration.
Rocuronium Bromide Injection is used as an adjuvant for general anesthesia, to facilitate tracheal intubation during routine induction of anesthesia, and to maintain neuromuscular blockade of skeletal muscles during surgery.
Related Articles
Russian court rules that Rio Tinto plc Sponsored ADR (RIO.US) must pay RUSAL (00468) approximately US$1.3 billion in damages; Mongolian OT copper mine interests may face enforcement
UBS Group AG: Maintains "Neutral" rating on Tesla, Inc. (TSLA.US), target price $385. AI narrative dominates the stock's pricing logic.
Memory supply shortage may persist until 2028! UBS Group AG raises Micron's (MU.US) earnings, bullish on HBM boom + incremental buybacks.
Russian court rules that Rio Tinto plc Sponsored ADR (RIO.US) must pay RUSAL (00468) approximately US$1.3 billion in damages; Mongolian OT copper mine interests may face enforcement
UBS Group AG: Maintains "Neutral" rating on Tesla, Inc. (TSLA.US), target price $385. AI narrative dominates the stock's pricing logic.
Memory supply shortage may persist until 2028! UBS Group AG raises Micron's (MU.US) earnings, bullish on HBM boom + incremental buybacks.
